News

Press Releases

Jan 22, 2019

CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

Jan 04, 2019

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease

Nov 21, 2018

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Nov 09, 2018

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

Presentations

Feb 12, 2019

CRISPR Therapeutics Corporate Presentation

Dec 01, 2018

Preclinical Development of CTX120, an Allogeneic CAR-T Cell Product Candidate Targeting BCMA

Nov 09, 2018

2018 Annual Meeting of The Society for Immunotherapy of Cancer (SITC) Poster: CRISPR/Cas9 Enables the Efficient Production of Allogeneic CAR-T Cells Engineered to Contain Multiple Genome Edits to Enhance Therapeutic T Cell Function

Oct 24, 2018

2017 Annual Report

View All Presentations

Events

Wednesday, June 13, 2018 8:00 a.m. PT

CRISPR Therapeutics at Goldman Sachs 39th Annual Global Healthcare Conference